HER-2 positivity rate in dogs with mammary carcinoma: a systematic review and meta-analysis

PDF (English)
DOI : https://doi.org/10.12681/jhvms.23639
E. UZABACI
Department of Biostatistics, Faculty of Veterinary Medicine, Bursa Uludag University, Bursa, Turkey
M.O. OZYIGIT
Department of Pathology, Faculty of Veterinary Medicine, Bursa Uludag University, Bursa, Turkey
I. ERCAN
Department of Biostatistics, Faculty of Medicine, Bursa Uludag University, Bursa, Turkey
O. ARDA
Department of Pathology, Uludag University Institute of Health Sciences, Bursa, Turkey
Résumé

Human epidermal growth factor receptor 2 (HER-2) plays an essential role in cell growth and survival. HER-2 overexpression occurs in 20-30% of human breast tumors and has prognostic value as it is associated with disease progression. HER-2 overexpression is also associated with tumor progression and metastasis in malignant mammary tumors of the canine. However, in the literature, different positivity classifications/scoring were used in the evaluation of HER-2 status, and there is no consensus in terms of scoring of HER-2 expression

in canine mammary tumors. In this study, it was aimed to estimate the HER-2 positivity rate by evaluating the results of the study using different positivity classifications by meta-analysis. In this context, by using ”HER-2 canine mammary tumor” keywords, Pubmed and Web of Science electronic databases were scanned until February 2019, and a total of 97 related studies were found. However, 20 of these studies were used for the analysis. Two different meta-analyses were performed to evaluate the HER-2 positivity status with “2+ and 3+” and “3+” scores. As a result, HER-2 positivity rates were determined at 25.87% and 25.99% for the studies using “2+ / 3+” scores and “3+” respectively for HER-2 positivity. Therefore, this result suggests that the rate of HER-2 positivity is similar between humans and dogs.

Article Details
  • Rubrique
  • Research Articles
Creative Commons License

Ce travail est disponible sous licence Creative Commons Attribution - Pas d’Utilisation Commerciale 4.0 International.

Authors who publish with this journal agree to the following terms:

· Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution Non-Commercial License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

· Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g. post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

· Authors are permitted and encouraged to post their work online (preferably in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.

Téléchargements
Les données relatives au téléchargement ne sont pas encore disponibles.
Références
Abadie J, Nguyen F, Loussouarn D, Peña L, Gama A, Rieder N, Belousov A, Bemelmans I, Jaillardon L, Ibisch C, Campone M (2018) Canine invasive mammary carcinomas as models of human breast cancer. Part 2: immunophenotypes and prognostic significance. Breast cancerresearch and treatment 10: 208-214.
Almasri NM, Al Hamad M (2005) Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan. Breast Cancer Research 7: R598-R604.
Araújo MR, Campos LC, Damasceno KA, Gamba CO, Ferreira E, Cassali GD (2016) HER-2, EGFR, Cox-2 and Ki67 expression in lymph node metastasis of canine mammary carcinomas: Association with clinical-pathological parameters and overall survival. Res Vet Sci 106:121-130.
Avci E (2018) Bayesian Meta-Analysis of Prevalence: Alzheimer’s Disease
in Europe. Turkiye Klinikleri J Biostat 10: 208-214.
Bertagnolli AC, Ferreira E, Dias EJ, Cassali GD (2011) Canine mammary mixed tumors: immunohistochemical expressions of EGFR and HER-2. Aust Vet J 89: 312-317.
Burrai GP, Tanca A, De Miglio MR, Abbondio M, Pisanu S, Polinas M, Pirino S, Mohammed SI, Uzzau S, Addis MF, Antuofermo E (2015) Investigation of HER2 expression in canine mammary tumors by antibody-based, transcriptomic, and mass spectrometry analysis: is the dog a suitable animal model for human breast cancer? Tumour Biol 36: 9083-91.
Campos LC, Silva JO, Santos FS, Araújo MR, Lavalle GE, Ferreira E, Cassali GD (2015) Prognostic significance of tissue and serum HER2 and MUC1 in canine mammary cancer. J Vet Diagn Invest 27: 531-5.
Charpin C, Garcia S, Bouvier C, Martini F, Lavaut MN, Allasia C, Bonnier P, Andrac L (1997) c-erbB-2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients’ overall and disease-free survival. British Journal of Cancer 75: 1667-1673.
Damasceno KA, Ferreira E, Estrela-Lima A, Gamba CO, Miranda FF, Alves MR, Rocha RM, de Barros ALB, Cassali GD (2016) HER-2 and EGFR mRNA Expression and Its Relationship with Versican in Malignant Matrix-Producing Tumors of the Canine Mammary Gland. PLoS One 11: e0160419.
Development Core Team R (2014) R: A language and environment for statistical computing. In: R version 3.4.0, https://www.R-project.org.
Dutra AP, Granja NVM, Schmitt FC, Cassali GD (2004) c-erbB-2 expression and nuclear pleomorphism in canine mammary tumors. Braz J Med Biol Res 37: 1673-1681.
Erdogan S, Kanık EA (2011) Determination of cut-off values for heterogeneity measurements according to Cochran Q heterogeneity test results in meta-analyses: A simulation study. Turkiye Klinikleri J Biostat 3:
-83.
Gama A, Alves A, Schmitt F (2008) Identification of molecular phenotypes in canine mammary carcinomas with clinical implications: application of the human classification. Virchows Arch 453: 123-32.
Gouvêa A, Milanezi F, Olson SJ, Leitao D, Schmitt FC, Gobbi H (2006) Selecting antibodies to detect HER2 overexpression by immunohistochemistry in invasive mammary carcinomas. Appl Immunohistochem Mol Morphol 14: 103-108.
Hsu WL, Huang HM, Liao JW, Wong ML, Chang SC (2009) Increased survival in dogs with malignant tumors overexpressing HER-2 protein and detection of a silent single nucleotide polymırphism in the canine HER-2 gene. Vet J 180: 116-123.
Im KS, Kim IH, Kim NH, Lim HY, Kim JH, Sur JH ( 2013) Breed-related differences in altered BRCA1 expression, phenotype, and subtype in malignant canine mammary tumors. Vet J 195: 366-72.
Kim JH, Im KS, Kim NH, Yhee JY, Nho WG, Sur JH (2011) Expression of HER-2 and nuclear localization of HER-3 protein in canine mammary tumors: histopathological and immunohistochemical study. Vet J 189: 318-22.
Kurilj AG, Hohšteter M, Artuković B, Severin K, Šoštarić-Zuckermann IC, Beck A, Seiwerth, S, Sabočanec R, Grabarević Ž (2011) Histopathological evaluation and immunohistochemical study of estrogen receptor alpha, HER-2, and Ki-67 in canine neoplastic mammary lesions. Veterinarski Arhiv 81: 709-722.
Martín de las Mulas J, Ordás J, Millán Y, Fernández-Soria V, Ramón y Cajal S (2003) Oncogene HER-2 in canine mammary gland carcinomas. Breast cancer research and treatment 80, 363-367.
Millanta F, Caneschi V, Ressel L, Citi S, Poli A (2010) Expression of vascular endothelial growth factor in canine inflammatory and non-inflammatory mammary carcinoma. J Comp Pathol 142: 36-42.
Muhammadnejad A, Keyhani E, Mortazavi P, Behjati F, Haghdoost IS (2012) Overexpression of her-2/neu in malignant mammary tumors; translation of clinicopathological features from dog to human. Asian Pac J Cancer Prev 13: 6415-21.
Nguyen F, Peña L, Ibisch C, Loussouarn D, Gama A, Rieder N, Belousov A, Campone M, Abadie J (2018) Canine invasive mammary carcinomas as models of human breast cancer. Part 1: natural history and prognostic factors. Breast Cancer Res Treat 167: 635-648.
Oh SY, Ryu HH, Yoo DY, Hwang IK, Kweon OK, Kim WH (2014) Evaluation
of FOXP3 expression in canine mammary gland tumors. Vet Comp Oncol 12: 20-28.
Peña L, Gama A, Goldschmidt MH, Abadie J, Benazzi C, Castagnaro M, Díez L, Gärtner F, Hellmén E, Kiupel M, Millán Y, Miller MA, Nguyen F, Poli A, Sarli G, Zappulli V, de las Mulas JM (2014) Canine Mammary Tumors: A Review and Consensus of Standard Guidelines on Epithelial and Myoepithelial Phenotype Markers, HER2, and Hormone Receptor Assessment Using Immunohistochemistry. Vet Pathol 51: 127-45.
Ressel L, Puleio R, Loria GR, Vannozzi I, Millanta F, Caracappa S, Poli A (2013) HER-2 expression in canine morphologically normal, hyperplastic and neoplastic mammary tissues and its correlation with the clinical outcome. Res Vet Sci. 94: 299-305.
Ross JS, Fletcher JA (1998) The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy. The Oncologist 3: 237-252.
Shin JI, Lim HY, Kim HW, Seung BJ, Sur JH (2015) Analysis of Hypoxia-Inducible Factor-1α Expression Relative to Other Key Factors in Malignant Canine Mammary Tumours. J Comp Pathol 153:101-10.
Silva ILD, Dias APM, Bertagnolli AC, Cassali GD, Ferreira E (2014) Analysis of EGFR and HER-2 expressions in ductal carcinomas in situ in canine mammary glands. Arq. Bras. Med Vet Zootec 66: 763-768.
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A (1989) Studies of the HER-2/neuproto-oncogene in human breast and ovarian cancer. Science 244:707-712.
Tas EO, Sag S, Ercan I (2018) Investigating the impact of polysomy 17 in breast cancer patients without amplification through meta-analysis. International Journal of Hematology and Oncology 28: 95-103.
Articles les plus lus par le même auteur ou la même autrice